Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 3Pancreatic Neoplasms 1Obesity 1Cardiotoxicity 1

Interventions

Doxorubicin 11Razoxane 5Dexrazoxane 5Electrocardiography 4Echocardiography 4Cyclophosphamide 4Vincristine 3Trastuzumab 3Granulocyte Colony-Stimulating Factor 3Filgrastim 3Exercise 3Etoposide 3Carvedilol 3Radiotherapy 2Prednisone 2Methotrexate 2Magnetic Resonance Spectroscopy 2Bleomycin 2salicylhydroxamic acid 1oblimersen 1hydrocortisone hemisuccinate 1dapagliflozin 1Vascular Stiffness 1VAP-cyclo protocol 1Tablets 1Silymarin 1Reverse Transcriptase Polymerase Chain Reaction 1Resistance Training 1Pulse Wave Analysis 1Palliative Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Cardiotoxicity × dapagliflozin × Clear all
NCT06888505 2025-09-18

DAPA-AIC

Hawler Medical University

Phase 2 Completed
90 enrolled

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡